穩健醫療(300888.SZ)：擬以7.28億元收購隆泰醫療55%的股權 其主要從事高端傷口敷料的研產銷
格隆匯4月10日丨 穩健醫療(300888.SZ)公佈，為進一步豐富公司產品線，拓展國內外業務渠道，完善公司戰略佈局，公司於2022年4月8日召開第三屆董事會第五次會議審議通過了《關於收購隆泰醫療55%股權的議案》，公司擬使用自有資金人民幣72754萬元向吳康平、黃樂培和吳狄收購其持有浙江隆泰醫療科技股份有限公司(“隆泰醫療”或“目標公司”)共計55%的股權，隆泰醫療的主營業務為高端傷口敷料(包括硅膠泡沫、水膠體、硅凝膠、水凝膠、薄膜敷貼及造口等產品)的研發、生產和銷售。交易各方已於2022年4月8日簽署了《關於浙江隆泰醫療科技股份有限公司之股權轉讓協議》。
此次交易的目標公司為隆泰醫療、其全資子公司西安隆特姆醫療科技有限公司(“西安隆特姆”)、根據交易方案將於此次交易交割前變更為隆泰醫療全資子公司的德清隆泰醫用硅膠製品有限公司(“隆泰硅膠”)和全資子公司杭州盛醫科技有限公司(“盛醫科技”)。隆泰醫療、西安隆特姆及隆泰硅膠主要從事高端傷口敷料業務；交易對方吳狄持有盛醫科技100%的股權，盛醫科技將在此次交易交割日之前注入隆泰醫療，由隆泰醫療持有其100%的股權，盛醫科技主要從事隆泰醫療產品在電商平台的銷售和運營業務，與隆泰醫療的高端傷口敷料業務具有協同性。隆泰醫療旗下其他與高端傷口敷料業務無相關性的子公司將在此次交易交割日之前進行剝離。
目標公司隆泰醫療主要從事高端傷口敷料(包括硅膠泡沫、水膠體、硅凝膠、水凝膠、薄膜敷貼及造口等產品)的研發、生產和銷售，具有行業領先的研發、生產與銷售能力，獲得了國際市場與國內市場優質客户的高度認可。2021年度，隆泰醫療實現銷售收入超人民幣3.5億元，其中高端傷口敷料產品合計實現銷售收入超人民幣2.8億元，在國內高端傷口敷料企業中處於行業領先地位。
因此，此次收購與穩健醫療打造高端傷口敷料行業龍頭的戰略高度契合，藉助雙方在客户、市場、產品、研發與生產的優勢，形成規模與協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
